Quest Diagnostics buys LabOne in $934M buyout

Quest Diagnostics is buying health screener LabOne of Lenexa, Kansas, for $934 million in cash and new debt. Quest is considered the dominant player in the health screening market and analysts cheered the union, saying that LabOne would bolster its presence in two key Midwestern markets. Quest and LabOne also do risk assessment work for health insurers.

- read this story from MarketWatch for more

Suggested Articles

Rachel Humphrey, M.D., who joined CytomX as chief medical officer after heading immuno-oncology at AstraZeneca and Eli Lilly, has made her exit.

Scientists have discovered a scorpion toxin could inspire treatments to block the inflammation that triggers chronic pain.

The phase 2 success keeps Hal Barron’s group on track to file for approval in multiple myeloma by the end of the year.